{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:17:45Z","timestamp":1790101065367,"version":"4.0.1"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2018.3874","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T18:05:21Z","timestamp":1541527521000},"page":"e183874","source":"Crossref","is-referenced-by-count":14,"title":["Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease"],"prefix":"10.1001","volume":"1","author":[{"given":"Katherine G.","family":"Garlo","sequence":"first","affiliation":[{"name":"Department of Medicine, Renal Division, Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Bates","sequence":"additional","affiliation":[{"name":"The Center for Patient Safety Research and Practice, Division of General Internal Medicine and Primary Care, Brigham & Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Clinical and Quality Analysis, Partners HealthCare, Somerville, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L.","family":"Seger","sequence":"additional","affiliation":[{"name":"The Center for Patient Safety Research and Practice, Division of General Internal Medicine and Primary Care, Brigham & Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Clinical and Quality Analysis, Partners HealthCare, Somerville, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Fiskio","sequence":"additional","affiliation":[{"name":"The Center for Patient Safety Research and Practice, Division of General Internal Medicine and Primary Care, Brigham & Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Clinical and Quality Analysis, Partners HealthCare, Somerville, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Charytan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Renal Division, Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"issue":"15","key":"zoi180177r1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency.","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"issue":"9721","key":"zoi180177r2","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"zoi180177r3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ahj.2008.01.031","article-title":"Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.","volume":"155","author":"Balamuthusamy","year":"2008","journal-title":"Am Heart J"},{"issue":"10","key":"zoi180177r4","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.2337\/dc06-0570","article-title":"Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.","volume":"29","author":"Winkelmayer","year":"2006","journal-title":"Diabetes Care"},{"issue":"21","key":"zoi180177r5","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"9311","key":"zoi180177r6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol.","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"zoi180177r7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/sj.ki.5000159","article-title":"ACE-inhibitor use and the long-term risk of renal failure in diabetes.","volume":"69","author":"Suissa","year":"2006","journal-title":"Kidney Int"},{"issue":"4","key":"zoi180177r8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi180177r9","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1097\/01.ASN.0000146423.71226.0C","article-title":"Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.","volume":"15","author":"Remuzzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"zoi180177r10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi180177r11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"issue":"6","key":"zoi180177r12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"issue":"5","key":"zoi180177r13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"zoi180177r14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"zoi180177r15","doi-asserted-by":"publisher","first-page":"j791","DOI":"10.1136\/bmj.j791","article-title":"Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study.","volume":"356","author":"Schmidt","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"zoi180177r16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2011.132","article-title":"Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success?","volume":"80","author":"Weir","year":"2011","journal-title":"Kidney Int"},{"issue":"20","key":"zoi180177r17","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1001\/jama.2016.16201","article-title":"US emergency department visits for outpatient adverse drug events, 2013-2014.","volume":"316","author":"Shehab","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"zoi180177r18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2215\/CJN.12881216","article-title":"Preventing emergency department use among patients with CKD: it starts with awareness.","volume":"12","author":"Patzer","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"zoi180177r19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2215\/CJN.06280616","article-title":"Emergency department use among patients with CKD: a population-based analysis.","volume":"12","author":"Ronksley","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"zoi180177r20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1471-2369-15-200","article-title":"Understanding physicians\u2019 behavior toward alerts about nephrotoxic medications in outpatients: a cross-sectional analysis.","volume":"15","author":"Cho","year":"2014","journal-title":"BMC Nephrol"},{"issue":"3","key":"zoi180177r21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/amiajnl-2013-001813","article-title":"Overrides of medication-related clinical decision support alerts in outpatients.","volume":"21","author":"Nanji","year":"2014","journal-title":"J Am Med Inform Assoc"},{"key":"zoi180177r22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of competing risks in survival analysis.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"9","key":"zoi180177r23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"zoi180177r24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2288-10-97","article-title":"Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes.","volume":"10","author":"Lim","year":"2010","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"zoi180177r25","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/ndt\/gft355","article-title":"When do we need competing risks methods for survival analysis in nephrology?","volume":"28","author":"Noordzij","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"zoi180177r26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney Int"},{"issue":"18","key":"zoi180177r27","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"issue":"4","key":"zoi180177r28","doi-asserted-by":"publisher","first-page":"e012674","DOI":"10.1136\/bmjopen-2016-012674","article-title":"What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? a systematic review and meta-analysis.","volume":"7","author":"Whiting","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"zoi180177r29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.kint.2016.11.019","article-title":"Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications.","volume":"91","author":"Weir","year":"2017","journal-title":"Kidney Int"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/1\/7\/e183874\/17295030\/garlo_2018_oi_180177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T17:27:09Z","timestamp":1550165229000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2018.3874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,11,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.3874","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]}}}